Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Letter to the Editor

A call for antimicrobial stewardship in patients with COVID-19: a nationwide cohort study in Korea

Dong Hoon Shin 1, #, Minsun Kang 2, #, Kyoung-Ho Song 1, Jaehun Jung 2, 3, **, Eu Suk Kim 1, *, Hong Bin Kim 1

1) Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2) Artificial Intelligence and Big-Data Convergence Centre, Gil Medical Centre, Gachon University College of Medicine, Incheon, Republic of Korea
3) Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Republic of Korea

ARTICLE INFO

Article history:
Received 10 September 2020
Received in revised form
16 October 2020
Accepted 20 October 2020
Available online 31 October 2020

Editor: L. Leibovici

To the Editor

The overuse of antibiotics for coronavirus disease 2019 (COVID-19) poses a threat [1]. Less than 8% of patients with COVID-19 have respiratory bacterial co-infections [2], and the current U.S. National Institutes of Health (NIH) guidelines do not recommend antibiotic prescription for patients with COVID-19 unless there is clinical suspicion of bacterial infection [3]. We reviewed the large nationwide insurance claims database of the Health Insurance Review and Assessment Service of Korea (HIRA) to identify the antibiotic prescription frequency for patients with COVID-19. As the HIRA is the only health insurance policy in Korea and is responsible for all hospitalization-related costs of COVID-19 patients, complete antibiotic claims data for the country could be evaluated. We retrospectively reviewed data on all adults (age ≥19 years) with confirmed COVID-19 admitted to hospitals or living treatment centres between 1st January and 15th May 2020. (Living treatment centres are non-hospital facilities where patients with mild COVID-19 can be admitted [4].)

Antibiotic use was quantified by days of therapy (DOTs) per 1000 patient-days. Antibiotics were classified into two groups: one group that covered either methicillin-resistant Staphylococcus aureus or Pseudomonas aeruginosa (anti-MRSA or anti-pseudomonal), and the other antibiotic group. Anti-MRSA or anti-pseudomonal antibiotics, such as glycopeptides, oxazolidinones, piperacillin—tazobactam, carbapenems, polymyxins, ceftazidime, or monobactams were mainly used for hospital-acquired pneumonia rather than community-acquired infection [5]. Fluoroquinolones were included in the other group because they were recommended as monotherapy for community-acquired pneumonia.

COVID-19 severity was classified as mild to moderate or severe to critical, according to the NIH guidelines [3]. Patients with a requirement for low-flow oxygen therapy (i.e., nasal cannula), high-flow oxygen therapy (i.e., high-flow nasal cannula or mechanical ventilation), inotropic drugs, or extracorporeal membrane oxygenation were classified as having severe to critical disease. Patients hospitalized for influenza from a national health insurance service sample cohort of 1 000 000 patients admitted in Korea between 2002 and 2015 were reviewed. Patients with influenza were analysed based on the same severity classification compared to patients with COVID-19. The study was approved by the Seoul National University Bundang Hospital Institutional Review Board (No. X-2008-633-902).

During the study period, of 6871 patients with COVID-19, 2419 (35.21%) and 536 (7.80%) were prescribed total antibiotics and anti-MRSA or anti-pseudomonal antibiotics, respectively (Table 1). Overall, 5928 patients (86.28%) and 943 patients (13.72%) had mild to critical and severe to critical disease, respectively, and 27.99% and 80.59% of these patients were prescribed antibiotics (Supplementary Table S1). Additionally, 2640 patients (38.42%) were prescribed lopinavir/ritonavir and 2082 (30.30%) hydroxychloroquine/chloroquine.

The total antibiotic use and anti-MRSA or anti-pseudomonal antibiotic use were 364.32 and 71.99 DOTs/1000 patient-days, respectively reviewed data on all adults (age ≥19 years) with confirmed COVID-19 admitted to hospitals or living treatment centres between 1st January and 15th May 2020. (Living treatment centres are non-hospital facilities where patients with mild COVID-19 can be admitted [4].)
Table 1
Clinical characteristics of patients with coronavirus disease 2019 (COVID-19) and antibiotic use

|                     | Total (n = 6871) | Anti-MRSA or anti-pseudomonal antibiotics* (n = 1883) | Other antibiotics (n = 536) | No antibiotic use (n = 4452) | p*       |
|---------------------|-----------------|------------------------------------------------------|---------------------------|-----------------------------|----------|
| Age, mean (±SD) (years) | 47.34 (±19.01) | 67.94 (±14.45) | 54.77 (±17.55) | 41.72 (±17.22) | <0.01    |
| Age group           |                 |                                                      |                           |                             |          |
| 19–64 years         | 5562 (80.95)    | 218 (40.67) | 1317 (69.94) | 4027 (90.45)    |          |
| >65 years           | 1309 (19.05)    | 318 (59.33) | 566 (30.06)  | 425 (9.55)       |          |
| Sex                 |                 |                                                      |                           |                             | <0.01    |
| Male                | 2773 (40.36)    | 263 (49.07) | 714 (37.92)  | 1796 (40.34)    |          |
| Female              | 4108 (59.64)    | 311 (50.93) | 1641 (62.08)| 2626 (59.66)    |          |
| Comorbidities       |                 |                                                      |                           |                             |          |
| Diabetes mellitus   | 1114 (16.21)    | 203 (37.87) | 421 (22.36)  | 490 (11.01)      | <0.01    |
| Cardiovascular disease | 589 (8.57)    | 136 (23.57) | 221 (11.74)  | 232 (5.21)       | <0.01    |
| Chronic respiratory disease | 1837 (26.74) | 209 (36.99) | 634 (33.67)  | 994 (22.33)      | <0.01    |
| Renal disease       | 215 (3.13)      | 46 (8.58)   | 67 (3.56)    | 102 (2.29)       | <0.01    |
| Chronic liver disease | 856 (12.46)   | 116 (21.64) | 298 (15.83)  | 442 (9.93)       | <0.01    |
| Peptic ulcer disease | 1040 (15.14)   | 141 (26.31) | 354 (18.80)  | 545 (12.24)      | <0.01    |
| Chronic neurological disease | 691 (10.06) | 184 (34.33) | 240 (12.75)  | 267 (6.00)       | <0.01    |
| Malignancy          | 306 (4.45)      | 53 (9.89)   | 110 (5.84)   | 143 (3.21)       | <0.01    |
| Musculoskeletal and rheumatological disease | 211 (3.07) | 27 (5.04)   | 72 (3.82)    | 112 (2.52)       | <0.01    |
| Immune deficiency and HIV infection | 3 (0.04) | 1 (0.19)   | 0 (0.0)      | 2 (0.04)         | 0.19     |
| Charlson comorbidity index, median (IQR) | 1 (0–2) | 2 (1–4)   | 1 (0–3)      | 0 (0–1)          | <0.01    |
| Disease severity of COVID-19 |                 |                                                      |                           |                             |          |
| Mild to moderate     | 5928 (86.28)    | 131 (24.44) | 1528 (81.15) | 4269 (95.89)    |          |
| Severe to critical   | 943 (13.72)     | 405 (75.56) | 355 (18.85)  | 183 (4.11)       |          |
| Lopinavir/ritonavir  | 2640 (38.42)    | 426 (79.48) | 1336 (70.95) | 878 (19.72)      | <0.01    |
| Hydroxychloroquine/chloroquine | 2082 (30.30) | 369 (68.84) | 1023 (54.33) | 690 (15.50)      | <0.01    |

MRSA, methicillin-resistant Staphylococcus aureus; HIV, human immunodeficiency virus; IQR, interquartile range; SD, standard deviation.

* Activity against either MRSA (such as glycopeptides and oxazolidinones) or Pseudomonas aeruginosa (such as piperacillin–tazobactam, carbapenems, polymyxins, cepazime, ceftazidime, and monobactams) were included, but fluoroquinolones were excluded because they are recommended as part of monotherapy for community-acquired pneumonia.

**Analysis of variance was used to compare anti-MRSA or anti-pseudomonal antibiotics, other antibiotics, and no antibiotic use groups.

respectively (Supplementary Table S1). The most commonly used antibiotics were fluoroquinolones (144.07 DOTs/1000 patient-days), third-generation cephalosporins (84.55 DOTs/1000 patient-days), and macrolides (46.16 DOTs/1000 patient-days). Antibiotics were prescribed more frequently in patients with severe to critical COVID-19, total antibiotic use was 1295.27 DOTs/1000 patient-days. Anti-MRSA or anti-pseudomonal antibiotic use. Moreover, a similar trend was observed with severe to critical COVID-19 (aOR 4.82, 95%CI 3.61–6.45, p < 0.01), and use of hydroxychloroquine/chloroquine (aOR 4.60, 95%CI 3.48–6.07, p < 0.01).

A 1:3 propensity score matching analysis performed with age, sex, and COVID-19 severity showed that severe to critical COVID-19 (p < 0.01, Supplementary Table S4), use of lopinavir/ritonavir (p < 0.01), and use of hydroxychloroquine/chloroquine (p < 0.01) were independently associated with anti-MRSA or anti-pseudomonal antibiotic use.

Overall, 42.95% of those with severe to critical COVID-19 were prescribed anti-MRSA or anti-pseudomonal antibiotics. The overuse of these antibiotics for pneumonia to treat potentially drug-resistant bacteria may lead to higher rates of acute kidney injury, Clostridium difficile infection, and colonization by multidrug-resistant P. aeruginosa and Acinetobacter baumannii [5,6]. In order to reduce such collateral damage, antibiotic treatment can be deferred until cultures confirm bacterial superinfection. Even if empirical antibiotic therapy is initiated in patients with severe to critical COVID-19, it should be re-evaluated by appropriate culture tests and stopped as soon as possible if the probability of bacterial coinfection is low [1,7].

A limitation of our study is that since microbiological test results were not reviewed in the HIRA database, the incidence of bacterial coinfection could not be determined. Moreover, it was impossible to distinguish between empirical antibiotic use and targeted antibiotic use for confirmed bacterial coinfection. In addition, the use of antibiotic combination therapy could not be determined from the data.

In conclusion, the rate of antibiotic use in Korea was high in patients with COVID-19, and anti-MRSA or anti-pseudomonal
antibiotics were frequently prescribed for severe to critical patients. As the COVID-19 pandemic continues, there is a need for antimicrobial stewardship to prevent collateral damage related to the overuse of antibiotics.

**Author contributions**

DHS and MK contributed equally to this work. JJ and ESK conceived and designed the study and had full access to all data. DHS, MK, JJ, and ESK collected and analysed the data. DHS and MK wrote the first draft of the manuscript. DHS, MK, KHS, JJ, ESK, and HBK participated in subsequent revisions.

**Transparency declaration**

The authors declare that they have no conflicts of interest. No funding was received for this work.

**Acknowledgements**

The authors thank Jongtak Jung and Nak-Hyun Kim of Seoul National University Bundang Hospital for data analysis assistance. The authors are grateful to the Ministry of Health and Welfare and the Health Insurance Review & Assessment Service of Korea for sharing invaluable national health insurance claims data. We would like to thank Editage (www.editage.co.kr) for English language editing.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2020.10.024.

**References**

[1] Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect 2020;26: 808–10.

[2] Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa530. May 2;ciaa530.

[3] COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health; 2020. Updated on 1 Sep, 2020. Last visited on 2 Sep, 2020, Available at: https://www.covid19treatmentguidelines.nih.gov/.

[4] Choe PG, Kang EK, Lee SY, Oh B, Im D, Lee HY, et al. Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in Korea. Korean J Intern Med 2020;35: 765–70.

[5] Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infections Diseases Society of America. Am J Respir Crit Care Med 2019;200: e45–67.

[6] Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006;64:7–15.

[7] Sieswerda E, De Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al. Recommendations for antibacterial therapy in adults with COVID-19—an evidence based guideline. Clin Microbiol Infect 2021;27:61–6.